Literature DB >> 11606397

Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen.

H Kobayashi1, J Lu, E Celis.   

Abstract

The melanocyte-associated antigen gp100 constitutes one of the most attractive targets for T-cell-based immunotherapy against malignant melanoma. Although several MHC class I-restricted epitopes have been identified for CTLs, thus far, only one MHC class II T helper epitope (restricted by HLA-DR4) has been described in the literature. Using an algorithm to identify promiscuous helper T-cell epitopes, here we describe three additional MHC class II-restricted epitopes from gp100. Whereas one T helper epitope, gp100(175-189), was restricted by the HLA-DR53 and DQw6 alleles, the T-cell responses to two other epitopes, gp100(74-89) and gp100(576-590), were restricted by HLA-DR7. Most interestingly, the newly identified helper T lymphocyte epitopes encompass or lie proximal to previously described CTL epitopes for this tumor-associated antigen. Together with the previously described HLA-DR4-restricted epitope, these T helper epitopes offer coverage for the majority of the human population. Moreover, the use of peptide vaccines containing both CTLs and T helper epitopes could offer therapeutic advantages over current approaches that focus solely on eliciting antitumor CTL responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606397

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.

Authors:  Paul F Robbins; Mona El-Gamil; Yong F Li; Gang Zeng; Mark Dudley; Steven A Rosenberg
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

2.  Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.

Authors:  Gang Zeng; Yong Li; Mona El-Gamil; John Sidney; Alexandro Sette; Rong-fu Wang; Steven A Rosenberg; Paul F Robbins
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

3.  A novel splice variant of Pmel17 expressed by human melanocytes and melanoma cells lacking some of the internal repeats.

Authors:  Sarah E Nichols; Dawn C Harper; Joanne F Berson; Michael S Marks
Journal:  J Invest Dermatol       Date:  2003-10       Impact factor: 8.551

Review 4.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

5.  In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes.

Authors:  Hiroya Kobayashi; Toshihiro Ngato; Keisuke Sato; Naoko Aoki; Shoji Kimura; Yuetsu Tanaka; Hitoshi Aizawa; Masatoshi Tateno; Esteban Celis
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

6.  Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.

Authors:  Lavakumar Karyampudi; Christopher J Krco; Kimberly R Kalli; Courtney L Erskine; Lynn C Hartmann; Karin Goodman; James N Ingle; Matthew J Maurer; Aziza Nassar; Chao Yu; Mary L Disis; Peter J Wettstein; John D Fikes; Melanie Beebe; Glenn Ishioka; Keith L Knutson
Journal:  Cancer Immunol Immunother       Date:  2009-07-21       Impact factor: 6.968

Review 7.  Melanosomes and MHC class II antigen-processing compartments: a tinted view of intracellular trafficking and immunity.

Authors:  Michael S Marks; Alexander C Theos; Graça Raposo
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 8.  Peptide epitope identification for tumor-reactive CD4 T cells.

Authors:  Hiroya Kobayashi; Esteban Celis
Journal:  Curr Opin Immunol       Date:  2008-05-20       Impact factor: 7.486

9.  Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.

Authors:  Eduardo Huarte; Jan Fisher; Mary Jo Turk; Diane Mellinger; Cathy Foster; Benita Wolf; Kenneth R Meehan; Camilo E Fadul; Marc S Ernstoff
Journal:  Cancer Lett       Date:  2009-06-06       Impact factor: 8.679

10.  MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes.

Authors:  Valentina Robila; Marina Ostankovitch; Michelle L Altrich-Vanlith; Alexander C Theos; Sheila Drover; Michael S Marks; Nicholas Restifo; Victor H Engelhard
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.